Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab with Carboplatin and Docetaxel in Advanced NSCLC
NCT00251498Phase 2Completed
- Sponsor
- Veeda Lifesciences
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KL-140 in non-small cell lung cancer (NSCLC), sponsored by Veeda Lifesciences. Primary endpoint: Objective Response Rate. Status: completed.
02
Drugs
KL-140
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00251498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00251498.